The bioactive glasses can lead to the promotion of growth of granulation tissue, while the gold nanoparticles (AuNPs) can induce the acceleration of wound healing including tissue regeneration, connective tissue formation, and angiogenesis. The aim of this study was to evaluate the impact of using the bioactive glass (BG) and BG-AuNPs composites on skin wound healing in experimental rat models for 14 days. Sol–gel derived BGs and BG-AuNPs composites mixed with Vaseline at 6, 12 and 18 wt% were used to evaluate the repair response of the skin. During the process of healing, granulomatous reaction was observed in the wound treated with 12 and 18 wt% BG-Vaseline ointments. Furthermore, a strong vascular proliferation and complete wound regeneration were found in 18%BG-AuNPs-Vaseline treated groups. The results derived from the performed investigations revealed that the 18% BG-AuNPs-Vaseline ointment is a promising candidate for wound healing applications.

No abstract

In the present study, scaffolds based on alginate‐pullulan‐bioactive glass‐ceramic with 0.5 and 1.5 mol % copper oxide were orthotopically implanted in experimental rat models to assess their ability to heal an induced bone defect. By implying magnetic resonance and imaging scans together with histological evaluation of the processed samples, a progressive healing of bone was observed within 5 weeks. Furthermore, as the regenerative process continued, new bone tissue was formed, enhancing the growth of irregular bone spicules around the scaffolds. A significantly higher amount of new bone was formed (37%) in the defect that received the composite with 1.5 mol % CuO (in glass‐ceramic matrix) content implant. Nevertheless, the bone regeneration obtained by scaffold with 0.5 mol % CuO implanted is comparable with the alginate‐pullulan‐β‐tricalcium phosphate/hydroxiapatite composite implant. The assessed amount of new bone formed was found to be between 29.75 and 37.15% for all the composition involved in the present study. During this process a regeneration process was shown when the alginate‐pullulan composite materials were involved, fact that indicate the great potential of these materials to be used in tissue engineering.

Composites based on sodium alginate, pullulan, and bioactive SiO -CaO-P O glass-ceramics with copper oxide were prepared as capsules. The obtained samples were structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), and scanning electron microscopy (SEM), and their bioactivity and biocompatibility properties were also tested both in vitro and in vivo by XRD, FT-IR, SEM, and high-resolution transmission electron microscopy. The fibroblast and osteoblast cell viability assays have shown good proliferation rates for all investigated samples, whereas all composites exhibited a good in vivo tolerance. The recovered composites after 5 weeks' in vivo and in vitro trials evidenced clear macroscopic alterations; particularly, after soaking in simulated body fluid, they have a corn flake aspect, and after their in vivo inoculation, a globular shape is retained. Different crystalline shapes of hydroxyapatite were formed after in vitro and in vivo trials for the glass-ceramic-polymer composites, the in vitro precipitated apatite was found to be nodular, and the in vivo experiment led to needlelike crystallites formation. Histopathological results showed a good biocompatibility with no significant signs of rejection by the host tissue. These assessments performed on the composites indicate that the studied materials can be considered without any doubt suitable candidates for future bone regeneration applications.

The aim of this study was to evaluate the effect of Altresyn® product (progesterone-based product) as a method for synchronization of oestrus in gilts. The gilts were divided into three experimental groups. The synthetic progesterone Altrenogest was fed daily to 39 gilts at 20 mg/gilts for 18 days. In case of the first group (n = 11 gilts) the treatment was performed using only Altresyn product. In group II (n=13 gilts) was administered the prostaglandin hormone (Prosolvin), 0.75 mg at 24 hours after Altrenogest treatment suppression. Group III (n=15 gilts) received one injections of PMSG hormone (Folligon), 500 IU/animal. Gilts were checked for oestrus twice daily and were artificially inseminated. All gilts expressed signs of oestrus between 3 and 6 days after withdrawal of Altrenogest. At the groups that were administered prostaglandin and PMSG there was a shorter duration of oestrus (group III -26.66 hours, group II -27.07 hours) compared to group I (28.54 hours). In this study, pregnancy rate ranged from 45.45% (group I) and 93.33 % (group III), while in group II the value slightly exceeded 50% (53.84%). In group I, the mean litter size was 11.6 piglets, in group II the mean value of farrowed piglets was 13.28 and 15 piglets in group III. Regarding the average number of weaned piglets in group I was 8.8, 12 in group II, while for the third group was 13.14. Altrenogest, the active ingredient in Altresyn® is effective for regulating the oestrus of gilts in commercial pig farms.